Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad study.
After the menopause, women naturally lose bone strength more quickly, which can make bones fragile and more likely to break. The RapaLoad study is researching new ways to protect bones and slow down this ageing process. Researchers are testing a medication called everolimus alongside physical exercise training. Everolimus targets a biological pathway inside our cells that controls cell growth and ageing. Scientists believe it may help the body keep making healthy bone. Taking part lasts for 24 weeks (around six months). During the study, participants have regular health checks, including simple blood tests, bone density scans, and fitness assessments. By measuring natural markers in the blood that show bone growth, scientists hope to see whether everolimus and exercise together can improve bone renewal. The results could help shape future treatments to prevent conditions like osteoporosis.
A colpo d'occhio
Di cosa tratta questo studio?
As women go through the menopause, their bodies produce less oestrogen. This natural drop in hormones can speed up bone loss, leading to thin and brittle bones—a condition known as osteoporosis. Over time, weaker bones increase the risk of fractures and can affect mobility and independence. Scientists are keen to find safe, proactive ways to protect bone density before significant damage occurs.
The RapaLoad study is looking at a drug called everolimus. This medicine works on a specific pathway inside our cells known as mTOR, which acts like a control switch for cell repair, growth, and ageing. Researchers believe that gently calming this pathway—particularly when paired with physical training—might encourage bones to stay strong and slow down the natural skeletal ageing process.
Over the course of 24 weeks, researchers will measure how the body responds. They will check specific proteins in the blood that show how quickly bone is being renewed, and they will use detailed bone scans to look at bone density and structure in the spine, hip, wrist, and lower leg. They will also assess muscle strength, balance, and general heart and metabolic fitness.
This is an early-stage (Phase II) research study. It is not a guaranteed cure or an immediate replacement for existing treatments, but it offers valuable clues about whether targeting the biology of ageing can protect women's bones for the future.
Punti chiave
- Tests whether everolimus and exercise can protect bone strength after the menopause.
- A Phase II clinical study lasting 24 weeks (about six months).
- Involves clinic visits for blood tests, painless bone scans, and fitness checks.
- Open to adult women in generally good health.
- Participation is fully voluntary, and you can leave the study at any time.
Chi può essere idoneo?
This study is open to adult women. While the broad medical criteria include women aged 18 and older, the main focus is on postmenopausal bone health, meaning it is designed for women who have reached or are going through the menopause.
Participants should be in generally good health. Because the trial involves both a study medicine and physical activity, you will need to be well enough to safely take part in moderate exercise checks, such as walking or cycling assessments.
You may not be able to join if you take certain medicines that could clash with everolimus, or if you have medical conditions affecting your heart, lungs, or immune system. The research team will carefully review your health records to ensure taking part is completely safe for you.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- I am a woman aged 18 or older.
- I have gone through or am currently going through the menopause.
- I am in generally good health and able to attend clinic appointments.
- I am able and willing to do light to moderate physical exercise.
- I am comfortable taking a study medicine and having blood tests and scans over 24 weeks.
Cosa comporta la partecipazione?
Taking part in the trial lasts for 24 weeks (approximately six months). During this time, you will take the study medication (everolimus) and may take part in a structured physical exercise programme. You will need to visit the study clinic at the start, and then around weeks 4, 12, and 24. Visits will involve routine blood tests to check bone health, quick and painless DXA bone scans to measure bone density, and high-detail scans of your wrist and shin. You will also complete simple physical tests to check your balance, muscle strength, and general fitness, along with routine checks of your weight, blood sugar, and cholesterol.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoDanimarca
Domande comuni
What is everolimus?
Everolimus is a medication that acts on cell ageing and growth signals. In this study, it is tested in low doses to see if it helps protect ageing bone tissue.
Are the bone scans painful or dangerous?
No. The scans (DXA and limb scans) are completely painless and non-invasive. They use very low levels of radiation, similar to the natural radiation we are exposed to in everyday life.
Do I need to be an athlete to do the exercise part?
Not at all. The exercise and fitness checks are designed to be safe, manageable, and tailored to everyday fitness levels.
Will taking part cost me any money?
No. All study medicines, scans, and clinic visits are provided free of charge, and travel expenses are usually covered by the trial.
Can I still take my regular prescriptions?
Many everyday medicines are fine to take, but the research doctors will review your exact medications to make sure they do not interact with everolimus.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.